'

Knowledge center

The place to find all the most innovative research and information on novel biologics and biosimilars.

Press Releases

European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis2

Amsterdam, Munich, Zug – Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorization (“MA”) to Ranivisio® (Ranivisio - Ranibizumab), a biosimilar to Lucentis® (ranibizumab-injection), for the treatment for several serious retinal diseases in the European Union (“EU”).i

Downloads

You can find all the latest presentations, brochures and fact sheets below covering our solutions and portfolio.

Let’s collaborate and deliver quality biosimilars together.

Get in touch for more information.